CP-101606 Pfizer Inc

Current Opinion in Investigational Drugs

Volumn 1, Issue 3, 2000, Pages 370-374

  Chazot, P L ^a  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLUTAMIC ACID; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRAXOPRODIL;

AMNESIA; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEAD INJURY; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033693599     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A potent new neuroprotectant which blocks N-methyl-D-aspartate responses
2. AntiParkinsonian effects of the novel NMDA antagonist CP-101,606
3. CP-101,606, a potent and selective antagonist of forebrain NMDA receptors: In vitro neuroprotective activity
4. Effects of the novel NMDA antagonists CP-98,113, CP-101,581 and CP-101,606 on cognitive function and regional cerebral edema following experimental brain injury in the rat
5. Pharmacological properties of acquired excitotoxicity in Chinese hamster ovary cells transfected with N-methyl-D-asparate receptor subunits
6. Mice deficient for the 55 kD tumor necrosis receptor are resistant to endottoxic shock, yet succumb to L. monnocytogenes infection
7. Brain 97 - Cerebral Blood Flow and Metabolism XVIIIth International Symposium, Baltimore, USA
8. Head Injury therapies
9. CP-283,097, a conformationally restricted analog of CP-101,606: Structure activity relations
10. CP-283,097, a potent antagonist of forebrain NMDA receptors
11. Differential effects of the NR2B selective NMDA receptor antagonists RO 25-6981 and CP-101,606, on cultured cortical neurons
12. Functional consequences of NR2 subunit composition in single recombinant N-methyl-D-asparate receptors
13. Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-D-asparate receptor, on the volume of ischemic brain damage off cytotoxic brain edema after middle cerebral artery occlusion in the feline brain
14. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist
15. The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat
16. CP-101,606, a potent neuroprotectant selective for forebrain neurons
17. Molecular dissection of native mammalian forebrain NMDA receptors containing the NR1 C2 exon
18. Effects of the NMDA antagonist CP-98,113 on regional cerebral edema and cardiovascular, cognitive and neurobehavioral function following experimental brain injury in the rat
19. Synthesis and SAR of 4-benzyl-4-hydroxy-N-(hydroxyphenoxylakyl)-piperidines as subtype selective NMDA receptor antagonists
20. Annual Report 1997 - Pfizer
21. Antinociceptive activity of CP-101606, an NMDA receptor NR2B subunit antagonist
22. Phenylethanolamines inhibit NMDA receptors by potentiating proton inhibition: Implications for novel neuroprotective strategies
23. Morgan Stanley Dean Witter: US Investment Research: Pfizer
24. Aiming at 4.7% market share in Japan by 2002: Mr Patterson of Pfizer
25. Drug development pipeline: NPC-567
26. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition
27. Biochemical evidence for the co-association of three N-methyl-D-asparate (NMDA) R2 subunits in recombinant NMDA receptors
28. CP-101,606, an NR2B selective NMDA receptor antagonist, does not block hippocampal LTP
29. Society of Neuroscience 29th Annual Meeting (Part XI) Miami Beach, FL, USA
30. NMDA receptor subtypes - Rationale for future CNS therapies
31. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn
32. American Chemical Society 219th National Meeting (Part II) Division of Medicinal Chemistry Symposia, San Francisco, CA, USA
33. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-asparate receptors
34. An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage
35. Drug development pipeline: CP-101606
36. Merrill Lynch: Global Healthcare Bulletin